Global CAR T Cell Therapy Market to Get Better Growth with Increasing Biologics
Posted by shriya on June 16th, 2021
The Chimeric Antigen Receptor (CAR) T cell therapy is recognized as an effective treatment for hematologic cancer such as leukemia, lymphoma, and multiple myeloma. The therapy appears to be effective for the treatment of adult among patients with relapsed/refractory multiple myeloma, or refractory mantle cell lymphoma (MCL) resistant to prior therapies.
According to Market Research Future (MRFR), the global CAR T cell therapy market is expected to reach a valuation of USD 8716.06 MN by 2025, registering a massive 58.52% CAGR throughout the forecast period (2017-2025). Increasing funding support from the governments as well as from the private entities for the R&D to develop and improve the CAR T cell technology predominantly drives the growth of the market.
Global CAR T Cell Therapy Market - Regional Analysis
North America is showing chances for retaining its dominance by holding the largest share in the global CAR T cell therapy market throughout the review period. Rapidly increasing cancer cases are acting as a major driving force for regional market growth. Moreover, well-defined per capita healthcare expenditure and rising numbers of care facilities offering the therapy alongside the availability of advanced devices contribute to the growth of the regional market.
Key players leading the global CAR T cell therapy market include Pfizer, Inc. (US), Novartis AG (Switzerland), Kite Pharma (US), Autolus Therapeutics PLC (UK), Cellectis (France), CARsgen Therapeutics (China), Sorrento Therapeutics (US), Juno Therapeutics (US), Legend Biotech (US), and Mustang Bio (US), among
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102
Market Research Future
+1 646 845 9312
Like it? Share it!
About the Authorshriya
Joined: May 18th, 2021
Articles Posted: 81
More by this author